File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3390/pharmaceutics12111025
- Scopus: eid_2-s2.0-85094910567
- PMID: 33114726
- WOS: WOS:000593794800001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Pulmonary Delivery of Biological Drugs
Title | Pulmonary Delivery of Biological Drugs |
---|---|
Authors | |
Keywords | aerosol inhalation lung monoclonal antibodies therapeutic proteins |
Issue Date | 2020 |
Publisher | MDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/pharmaceuticals/ |
Citation | Pharmaceutics, 2020, v. 12, p. article no. 1025 How to Cite? |
Abstract | In the last decade, biological drugs have rapidly proliferated and have now become an important therapeutic modality. This is because of their high potency, high specificity and desirable safety profile. The majority of biological drugs are peptide- and protein-based therapeutics with poor oral bioavailability. They are normally administered by parenteral injection (with a very few exceptions). Pulmonary delivery is an attractive non-invasive alternative route of administration for local and systemic delivery of biologics with immense potential to treat various diseases, including diabetes, cystic fibrosis, respiratory viral infection and asthma, etc. The massive surface area and extensive vascularisation in the lungs enable rapid absorption and fast onset of action. Despite the benefits of pulmonary delivery, development of inhalable biological drug is a challenging task. There are various anatomical, physiological and immunological barriers that affect the therapeutic efficacy of inhaled formulations. This review assesses the characteristics of biological drugs and the barriers to pulmonary drug delivery. The main challenges in the formulation and inhalation devices are discussed, together with the possible strategies that can be applied to address these challenges. Current clinical developments in inhaled biological drugs for both local and systemic applications are also discussed to provide an insight for further research |
Persistent Identifier | http://hdl.handle.net/10722/293409 |
ISSN | 2023 Impact Factor: 4.3 2023 SCImago Journal Rankings: 0.845 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Liang, W | - |
dc.contributor.author | PAN, HW | - |
dc.contributor.author | Vllasaliu, D | - |
dc.contributor.author | Lam, JKW | - |
dc.date.accessioned | 2020-11-23T08:16:20Z | - |
dc.date.available | 2020-11-23T08:16:20Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Pharmaceutics, 2020, v. 12, p. article no. 1025 | - |
dc.identifier.issn | 1424-8247 | - |
dc.identifier.uri | http://hdl.handle.net/10722/293409 | - |
dc.description.abstract | In the last decade, biological drugs have rapidly proliferated and have now become an important therapeutic modality. This is because of their high potency, high specificity and desirable safety profile. The majority of biological drugs are peptide- and protein-based therapeutics with poor oral bioavailability. They are normally administered by parenteral injection (with a very few exceptions). Pulmonary delivery is an attractive non-invasive alternative route of administration for local and systemic delivery of biologics with immense potential to treat various diseases, including diabetes, cystic fibrosis, respiratory viral infection and asthma, etc. The massive surface area and extensive vascularisation in the lungs enable rapid absorption and fast onset of action. Despite the benefits of pulmonary delivery, development of inhalable biological drug is a challenging task. There are various anatomical, physiological and immunological barriers that affect the therapeutic efficacy of inhaled formulations. This review assesses the characteristics of biological drugs and the barriers to pulmonary drug delivery. The main challenges in the formulation and inhalation devices are discussed, together with the possible strategies that can be applied to address these challenges. Current clinical developments in inhaled biological drugs for both local and systemic applications are also discussed to provide an insight for further research | - |
dc.language | eng | - |
dc.publisher | MDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/pharmaceuticals/ | - |
dc.relation.ispartof | Pharmaceutics | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | aerosol | - |
dc.subject | inhalation | - |
dc.subject | lung | - |
dc.subject | monoclonal antibodies | - |
dc.subject | therapeutic proteins | - |
dc.title | Pulmonary Delivery of Biological Drugs | - |
dc.type | Article | - |
dc.identifier.email | Lam, JKW: jkwlam@hku.hk | - |
dc.identifier.authority | Lam, JKW=rp01346 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3390/pharmaceutics12111025 | - |
dc.identifier.pmid | 33114726 | - |
dc.identifier.pmcid | PMC7693150 | - |
dc.identifier.scopus | eid_2-s2.0-85094910567 | - |
dc.identifier.hkuros | 318756 | - |
dc.identifier.volume | 12 | - |
dc.identifier.spage | article no. 1025 | - |
dc.identifier.epage | article no. 1025 | - |
dc.identifier.isi | WOS:000593794800001 | - |
dc.publisher.place | Switzerland | - |